Background. Mortality among patients with Clostridium difficile infection (CDI) is high. Because of high age and multiple underlying diseases, CDI-related mortality is difficult to estimate. We estimated CDI-related mortality in an endemic situation, not influenced by outbreaks and consequently certain patients and C. difficile strains.
Clostridium difficile infection (CDI) emerged in the beginning of the 21st century and is now the leading cause of antibiotic-associated diarrhea [1, 2] . Outbreaks in the Western world coincided with the emergence of a new type of C. difficile: polymerase chain reaction (PCR) ribotype 027 [3] . This type was postulated to produce more toxins A and B, the major virulence factors of C. difficile, in vitro [4, 5] , and was frequently associated with severe disease in patients [3, 6, 7] . Within this new era of CDI, numerous studies focused on mortality rates among CDI patients. Studies were mainly conducted in outbreak situations or specific populations such as patients treated in intensive care units or surgical wards [3, 8, 9] . Mortality rates during outbreaks varied, owing to the study population and the PCR ribotype that was associated with the outbreak [8, 10, 11] . Studies in nonoutbreak situations are less common. A Canadian surveillance study that identified 1430 CDI patients, of whom 282 were diagnosed during an outbreak, showed that allcause mortality in a setting of low incidence differed considerably from an outbreak situation (15% vs 23% after 30 days) [12] .
Similar to all-cause mortality, CDI-related death increased at least 4-fold between 1999 and 2006 [13, 14] . However, CDIrelated death is difficult to objectify, because the existence of comorbidities is a risk factor for acquisition of the disease. Multiple outbreak investigations have concluded that CDIrelated mortality frequently (14%-19%) occurs within 30 days [3, 11, 15] . Surprisingly, an endemic study that matched cases and controls on the propensity to develop CDI concluded that CDI had no direct effect on mortality in the first 60 days. After 3 months, however, the attributable mortality was 6% [16] .
We performed a large multicenter cohort study in an endemic situation to estimate the mortality among CDI patients that is not influenced by outbreaks at certain wards or hospitals and consequently certain patient groups. We also estimated the CDI-related mortality.
METHODS

Study Aims
The first aim of our study was to determine the absolute allcause mortality risk of CDI patients. The second aim was to determine the CDI-related mortality (1) as the excess mortality when compared to 2 control groups and (2) according to the National Registration of Death certificates.
Patients and Definitions
Between 1 July 2006 and 30 April 2009, 13 Dutch hospitals prospectively included CDI patients in the study. The total monthly number of admissions and patient days and type of hospital (university or local) were collected to study the incidence of CDI.
All unformed stool samples of patients who were hospitalized for ≥2 days were tested for C. difficile in addition to the patients for whom a C. difficile test was requested. The method to detect C. difficile toxins differed per hospital; 6 hospitals used the Immunocard (Meridian, bioMérieux), 4 used a cytotoxicity assay, and 3 used the Vidas toxin A and/or B enzyme immunoassay (Meridian, bioMérieux). Hospitalized patients with unformed stool and a positive assay for C. difficile toxin were considered to have CDI. Patients were included only once.
To calculate the relative mortality rate, CDI patients were individually matched to 2 hospitalized control patients: (i) without diarrhea and (ii) with diarrhea and a negative test for the toxin of C. difficile. To maximize the feasibility of the study for the participating hospitals, matching was only requested during a prespecified period of ≥6 consecutive months. Nine hospitals agreed to these terms, consisting of both academic (n = 5) and local (n = 4) hospitals (Figure 1) . Matching was based on ward of diagnosis and time of hospitalization (control patients were hospitalized within 14 days of the day on which CDI was diagnosed in the CDI patient). When several potential control patients were eligible, the first patient on the alphabetical ward list was chosen. A patient with non-CDI diarrhea fulfilling the matching criteria was not always available.
Demographic data and clinical information such as the date of onset of diarrhea, prior underlying diseases, prior medication, and prior abdominal surgery were collected for all patients. "Prior" was defined as within 3 months before the start of diarrhea. When symptom onset was unclear, the date of diagnosis was used as a proxy. For nondiarrheal patients, "prior" was defined as within 3 months before the reference date. This date was calculated by adding the duration of hospitalization of the matched CDI patient (admission date to start of diarrhea) to the admission date of the patient without diarrhea. Matched CDI patients and controls without diarrhea therefore had a similar duration of hospitalization. In the matched cohort, we additionally gathered data on prior admissions and the Charlson comorbidity index (CCI) before the current hospitalization [17] . Data were extracted by manual review of the electronic and paper patient chart and contact with the physician in charge. In each facility, data were collected on a standardized questionnaire by trained research personnel. In patients with CDI, we requested the C. difficile strain for PCR ribotyping [18] . Four hospitals responded well to this request (strains submitted in >75%), while 5 submitted 36%-68% and 4 hospitals submitted <10%. The study protocol was approved by the Medical Review Ethics Committee of each participating hospital.
Outcome Measures
Follow-up started at diagnosis or the reference date. Dates of death were ascertained by searching the Dutch Civil Registration System in which dates of death or emigration of all Dutch residents are registered. Information on the cause of death was retrieved from the National Registry of Death certificates, where up to 4 different causes of death are registered per patient using the International Classification of Diseases, 10th Revision (ICD-10) [19] . Patient data were linked to the registry of death certificates by the Netherlands Office of Statistics, thereby guaranteeing anonymity.
The cause of death was known for >90% of the patients that died within 1 year. We used the following ICD-10 codes for classification of CDI-related mortality: A04.7 (C. difficile enterocolitis); A04.8 and A48.8 (used in the Netherlands to indicate colitis due to Clostridium and Clostridium infection, not specified as C. difficile); and the codes for a gastroenteritis of presumed infectious origin, septicemia due to anaerobes, and other bacterial infections of an unspecified site (A09, A41.4, and A49.8). These latter codes, in combination with the mention of C. difficile in the text of the death certificate, are used in England and Wales to select patients with CDI as a cause of death [20] . In the Netherlands, the text of death certificates is not available, which might have introduced misclassification.
Statistical Analysis
Proportions were compared using the χ 2 test. Kaplan-Meier was used to calculate the mortality risk and rate and show the 1-year mortality. Proportional hazards modeling (Cox regression) was used to adjust for the effects of age, sex, and CCI. To limit confounding by underlying diseases, we additionally adjusted for 6 ICD-10 chapters (method 1), and for medication, admission, and abdominal surgery in the 3 months prior to the onset of diarrhea and admission to an intensive care unit (method 2). Results are presented as hazard ratios (HRs) with accompanying 95% confidence intervals (95% CIs). Statistical significance was considered to have been reached if a 2-sided P value was ≤.05. We used PASW Statistics version 18.0 (SPSS Inc, Chicago, Illinois) and Stata software package 10.1 (StataCorp, College Station, Texas) for our analyses.
RESULTS
Incidence
In the 34-month study period, 1 030 202 hospital admissions, including 1366 patients with CDI, occurred. The mean incidence was 1.33 per 1000 admissions (2.1 per 10 000 patientdays), varying between 0.74 and 2.30 per 1000 admissions among the 13 participating hospitals. The monthly variation of CDI incidence within hospitals was small; however, in 2 hospitals the incidence exceeded 6.00 per 1000 admissions during one month. No seasonal variation was observed (data not shown).
CDI Cohort
The mean age of the 1366 CDI patients was 63 years; half of them were male (50.7%). Eighty-six percent had healthcareassociated CDI (development of diarrhea >48 hours after admission or <12 weeks after discharge). Underlying diseases were common and 82.4% of patients received antibiotic therapy in the 3 months prior to diarrhea ( Table 1 ). The most frequently found PCR ribotype among CDI patients was type 014 (112/689; 16.3%). Other frequently found types were 078 (11.0%), 001 (8.3%), and 027 (8.0%). Patients with a typing result resembled those without, with respect to age (mean, 62.4 vs 62.8 years), underlying diseases (mean CCI, 2.6 vs 2.8), medication use, and outcome. Of 1350 CDI patients with known follow-up, 177 patients died within 30 days, accounting for a mortality risk of 13.1% (47.3 per 10 000 person-years). One year after diagnosis, 497 patients had died (36.8%; Figure 2 ) and in 1% (10/1145) a colectomy was performed. The 30-day mortality increased with age (Table 2) , with the highest case fatality observed for persons between 80 and 89 years (52/244; 21.3%) and >90 years of age (8/39; 20.5%). PCR ribotype 027 was associated with the highest 30-day mortality (12/55; 21.8%). Compared to patients with CDI due to other PCR ribotypes, patients with type 027 had a significantly higher mortality risk (21.8% vs 11.3%; Cox regression analysis: HR, 2.1 [95% CI, 1.1-3.8]; P = .02). The mortality among patients with type 027 remained significantly higher after adjustment for age and sex (HR, 1.9 [95% CI, 1.0-3.5]; P = .04).
Matched Cohort
The 317 CDI patients that were matched to controls without diarrhea (n = 317) and, if available, controls with diarrhea Medication use and abdominal surgery were positive when the patient used/experienced this in the 3 months prior to the start of diarrhea. Admission was positive when the patient was admitted to a healthcare facility in the 3 months prior to the start of diarrhea, excluding the current hospitalization. ICU admission was positive when a patient was admitted to an ICU in the 3 months prior to the start of diarrhea or reference date (could be during the current hospitalization).
Abbreviations: CDI, Clostridium difficile infection; ICU, intensive care unit; PCR, polymerase chain reaction; SD, standard deviation. (n = 232), resembled the total cohort of CDI patients (Table 1) . Statistically significant differences between matched CDI patients and the total population were lower frequency of respiratory diseases (25% vs 30%), higher frequency of circulatory diseases (54% vs 44%), and more frequent use of immunosuppressive agents (43% vs 36%). Treatment for CDI consisted of metronidazole (234/309; 76%), vancomycin (2%), or a combination of both (11%). Eleven percent were not treated for CDI. The mean age of controls without and with diarrhea was 60 and 58 years, respectively, compared to 62 years in matched CDI patients (P = .17 and P = .03, respectively). Underlying diseases were more prevalent in CDI patients, except for endocrine diseases. The mean CCI was higher among CDI patients than among control patients without and with diarrhea: 2.68, 2.28, and 2.42, respectively (P = .01 and P = .04). Sixteen percent of CDI patients (51/317) had an index of ≥5.
Mortality in CDI
Mortality of CDI patients and controls is displayed in Figure 2 and Table 3 . Among matched CDI patients, 14.8% died within 30 days (53.9 per 10 000 person-years), which was similar to the cohort of CDI patients (14.8% vs 13.1%; P = .21). The 30-day mortality rate among control patients without and with diarrhea was considerably lower: 5.4% and 8.6% (P < .01 and P = .01), respectively.
Within the first 30 days, mortality among CDI patients was 2.9 times higher than among nondiarrheal controls (HR, 2.9 [95% CI, 1.7-5.1]). After adjustment for baseline differences in age, sex, and CCI, CDI was still associated with a 2.5-fold increased 30-day mortality rate (95% CI, 1.4-4.3). The HR decreased to 1.8 (95% CI, .9-3.5) and 0.9 (95% CI, .6-1.4) within 3 months and 1 year, respectively. Overall, CDI was associated with a 1.5 times increased mortality (95% CI, 1.1-2.0) in the first year. Results were similar when additional adjustments for underlying diseases or medication and admissions were made (methods 2 and 3 in Table 3 ), or when the in-hospital mortality was assessed instead of the 30-day mortality (HR according to method 1: 2.3 [95% CI, 1.1-4.7]). Postdischarge mortality (a proxy for long-term mortality) with up to 1 year of follow-up was not significantly different between matched CDI patients and nondiarrheal controls (HR according to method 1: 1.0 [95% CI, .7-1.5]).
When CDI patients were compared to controls with diarrhea, the HR for 30-day mortality was 1.9 (95% CI, 1.1-3.3 [58.0 for CDI vs 29.9 for controls per 10 000 patient-years]). In multivariable analysis, this mortality rate was 1.6 (95% CI, .9-2.8). 
CDI-Related Mortality According to Death Certificates
Of the 497 patients who died within 1 year, death certificates could be accessed in 93% (462/497). According to these certificates (Table 4) , the cause of death was related to CDI in 46 patients (10.0% of all deaths; 3.7% of all CDI patients). Three certificates specifically coded death due to C. difficile enterocolitis, 36 had a code for Clostridium infection/colitis, and 7 had one of the unspecific codes possibly related to CDI (A09, n = 2; A41.4, n = 5). Most (72%; 33/46) CDI-related deaths occurred within 30 days. Eleven other patients died within 3 months; only 2 patients died thereafter (105 and 193 days, respectively). In contrast, no control patients had a primary or secondary cause of death related to CDI.
PCR ribotypes were known for 25 patients with CDI-related codes on their death certificates. Type 078 (6/25; 24%), type 045, and type 001 (both 3/25; 12%) were the most common. The primary cause of death was a neoplasm or a disease of the respiratory or circulatory tract in most CDI patients as well as controls (Table 4) .
DISCUSSION
During the study period, we experienced a stable, low incidence of CDI in hospitals. Even in this endemic setting mortality among hospitalized CDI patients was high: 13% within 30 days. This percentage was only slightly lower than observed during outbreaks (15% to 25% within 30 days) [3, 8, 11, 12] . Compared to matched patients without diarrhea, the 30-day mortality rate of CDI patients in our study was increased 2.5-fold, a rate estimate consistent with a Canadian study with a 10-fold higher incidence [21] . This highlights CDI as a serious healthcare problem, even in absence of an outbreak.
Our study showed that CDI-related mortality occurred mainly within 30 days; long-term consequences of CDI (mortality after 90 days) were small. As the 1-year mortality in CDI patients was 50% higher (adjusted HR) than in controls (1-year mortality risk: 21.5%), we estimate that CDI-related mortality risk is about 10% (50% of 21.5%). Given a yearly incidence of 2700 CDI patients in the Netherlands [22] , approximately 270 deaths annually (10%) are estimated to occur as a consequence of the infection. This corresponds to 0.2% of all deaths in the Netherlands. Although this number is lower than the number of CDI-related deaths in England and Wales (1.1% of all deaths; derived from death certificates) [20] , it underscores the importance of CDI as a cause of death in the Netherlands.
According to the death certificates, 3.7% of the CDI patients died as a consequence of CDI. This is clearly less than our estimated CDI-related mortality risk (10%). Although we used relatively nonspecific ICD-10 codes, in addition to a specific code (A04.7), to estimate CDI-related death, a majority (72%) of the patients with CDI-related ICD-10 codes died within 30 days of their diagnosis. Furthermore, nonspecific ICD-10 codes were not observed in control patients. Therefore, we believe that we did not overestimate CDI-related mortality. Rather, our study indicates that death certificates lack sensitivity to provide a correct estimate of the CDI-related mortality, which is in accordance with findings from studies in the United Kingdom [23] and Canada [24] , who report that death certificates may be inaccurate to investigate CDI-related death [14, 25] .
A large number of C. difficile strains were available for further typing (n = 689; 50.4%) and we were able to relate these types to patient characteristics. Because patients without typing results resembled typed patients with respect to clinical characteristics and outcome, and most hospitals either responded well or did not respond at all to the typing request, we believe that selection bias based on severity of disease is limited. The PCR ribotypes found in our study are also common in Europe [26] . The finding that type 027 was significantly associated with a higher 30-day mortality rate adds evidence to the hypothesis that type 027 has hypervirulent characteristics [3, 11, 27] . Mortality risk is stratified by age decades. Additionally, stratification displayed the 4 most frequently found polymerase chain reaction (PCR) ribotypes, a group of all other types combined (n = 387), and a group of patients with Clostridium difficile infection but without a PCR ribotype result.
Abbreviation: PCR, polymerase chain reaction. The rate ratio was calculated using Cox regression analysis. In method 1 we used age (continuous variable), sex, and Charlson comorbidity index (CCI; continuous variable) as adjusting variables. Method 2 adjusted for these 3 variables, supplemented with adjustment for the 6 most frequently found ICD-10 chapters among Clostridium difficile infection (CDI) patients and controls (dichotomous variables: chapter II, Neoplasms; chapter IV, Endocrine, Nutritional, and Metabolic Diseases; chapter IX, Diseases of the Circulatory System; chapter X, Diseases of the Respiratory System; chapter XI, Diseases of the Digestive System; chapter XIV, Diseases of the Genitourinary System). In method 3 we adjusted for age, sex, CCI, medication in the previous 3 months (antibiotics, immunosuppressives, chemotherapeutic agents), prior admission, prior abdominal surgery, and admission to an intensive care unit in the 3 months prior to diarrhea (see Table 1 for exact information on the occurrence of these variables in CDI patients and controls).
Abbreviations: CCI, Charlson comorbidity index; CDI, Clostridium difficile infection; CI, confidence interval; HR, hazard ratio; ICD-10, International Classification of Diseases, Tenth Revision; py: patient-years. The multicenter approach and large timeframe of our study resulted in 1366 CDI patients among >1 million hospital admissions. This design enabled us to analyze CDI in a low-incidence environment with numerous different PCR ribotypes, which ensured us that our conclusions were not substantially influenced by outbreaks with specific types among specific groups of patients. Another strength of our study is that data were complete and carefully obtained because they were extracted by manual review of patient charts and contact with the treating physician, after which outcome data were checked using national registries.
Our study has a few limitations. First, we had access to 2 control groups that were selected by the criterion of presence vs absence of diarrhea. A control group selected without consideration of this criterion would have been more representative [28, 29] . Because only 10% of hospitalized patients experience diarrhea during their hospitalization, the comparison of CDI patients to controls without diarrhea was considered the most reliable. However, when we analyzed both control groups in one group, we found a similar 1-year CDI-related mortality, which therefore did not influence our conclusions. A second limitation is the possibility that we failed to identify all CDI patients due to the low sensitivity of enzyme immunoassay (EIA) [30] . Including EIA-negative patients as diarrheal controls could have led to underestimation of the CDI-related mortality rate, which is a second motive to report the comparison of CDI patients to controls without diarrhea as the most reliable. Finally, as with any observational study, we cannot rule out residual confounding due to underlying diseases in the estimation of the CDI-related mortality. In our analysis we adjusted for age, sex, and underlying diseases (using 3 methods). Matching accounted for hospital and ward of admission. Additionally, CDI patients and controls without diarrhea had a similar duration of hospitalization. By taking into account parameters for chronic underlying diseases (eg, CCI) and acute disease (duration of hospitalization), we believe we have provided a good estimate of the true excess mortality in CDI patients.
In conclusion, our large multicenter study shows that allcause mortality rates among CDI patients are high and that CDI increases mortality 2.5-fold, even in an endemic situation. This highlights the considerable disease burden and clinical impact of CDI, even in absence of an outbreak and emphasizes the need for preventive strategies and novel therapeutic approaches.
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